Message #44 From:
NewsBot Date: December 19, 2006 06:00:00 AM
OSCI News Oscient Pharmaceuticals to Present at 25th Annual JPMorgan Healthcare Conference - Webcast of presentation available Thursday, January 11, 2007 at 11:30 AM PT -
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in
the 25th Annual JPMorgan Healthcare Conference
on January 11, 2007 in San Francisco. President and CEO, Steven
Rauscher, will provide an overview of the Company including details on
the continued launch of ANTARA(R) 130 mg (fenofibrate) capsules and the
third winter season for FACTIVE(R) (gemifloxacin mesylate) tablets. The
presentation will begin at 11:30 AM PT (2:30 PM ET) on Thursday and will
be webcast through the Company’s website at www.oscient.com.
An archive of the webcast will also be available for three months.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage
biopharmaceutical company marketing two FDA-approved products with its
national primary care sales force. ANTARA(R) 130 mg (fenofibrate)
capsules is indicated for the adjunct treatment of hypercholesterolemia
(high blood cholesterol) and hypertriglyceridemia (high triglycerides)
in combination with diet. FACTIVE(R) (gemifloxacin mesylate) tablets is
an antibiotic approved for the treatment of acute bacterial
exacerbations of chronic bronchitis and community-acquired pneumonia of
mild to moderate severity. Oscient also has a novel, late-stage
antibiotic candidate, Ramoplanin, under investigation for the treatment
of Clostridium difficile-associated disease (CDAD).
